For patients with chronic obstructive pulmonary disorder (COPD), long-term inhaled corticosteroid (ICS) treatment is ...
Long-term inhaled corticosteroid (ICS) use for chronic obstructive pulmonary disease/ COPD (lung disease) may increase the ...
Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended as first-line treatment unless patients have asthma/COPD overlap or frequent ...
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...
Background and goal: Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended as first-line treatment unless patients have asthma ...
Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...
The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...
The EMA has agreed to review GSK’s application to expand Nucala’s use as an add-on maintenance for individuals with COPD.